Citation: | LI Zihuang, LI Xianming, YANG Dong, XU Gang, ZHOU Yayan, WU Shihai, LI Zhuangling. Clinical Analysis of Temozolomide Combined with Radiotherapy on High-grade Glioma[J]. Cancer Research on Prevention and Treatment, 2015, 42(02): 185-189. DOI: 10.3971/j.issn.1000-8578.2015.02.019 |
[1] |
Omuro A, DeAngelis LM. Glioblastoma and other malignant gliomas, a clinical review[J]. JAMA, 2013, 310(17): 1842-50.
|
[2] |
Dolecek TA, Propp JM, Stroup NE, et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005-2009[J]. Neuro Oncol, 20 12, 14 suppl 5: v1-49.
|
[3] |
Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma[J]. N Engl J Med, 2005, 352(10): 987-96.
|
[4] |
Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase Ⅲ study: 5- year analysis of the EORTC-NCIC trial[J]. Lancet Oncol, 2009, 10 (5): 459-66.
|
[5] |
Oike T, Suzuki Y, Sugawara K, et al. Radiotherapy plus concomitant adjuvant temozolomide for glioblastoma: Japanese mono-institutional results[J]. PLoS One, 2013, 8(11): e78943.
|
[6] |
DeAngelis LM. Anaplastic glioma: how to prognosticate outcome and choose a treatment strategy[J]. J Clin Oncol, 2009, 27(35): 58 61-2.
|
[7] |
Omar AI, Mason WP. Temozolomide: the evidence for its therapeutic efficacy in malignant astrocytoma[J]. Core Evid, 2010, 4: 93-111.
|
[8] |
Dresemann G. Temozolomide in malignant glioma[J]. Onco Targets Ther, 2010, 3: 139-46.
|
[9] |
Scoccianti S, Magrini SM, Ricardi U, et al. Radiotherapy and temozolomide in anaplastic astrocytoma: a retrospective multicenter study by the Central Nervous System Study Group of AIRO (Italian Association of Radiation Oncology)[J]. Neuro Oncol, 2012, 14(6): 798-807.
|
[10] |
Zhang L, Wu X, Xu T, et al. Chemotherapy plus radiotherapy versus radiotherapy alone in patients with anaplastic glioma: a systematic review and meta-analysis[J]. J Cancer Res Clin Oncol, 20 13,139(5): 719-26.
|
[11] |
Gutenberg A, Bock HC, Reifenberger G, et al. Toxicity and survival in primary glioblastoma patients treated with concomitant plus adjuvant temozolomide versus adjuvant temozolomide: results of a single-institution, retrospective, matched-pair analysis[J]. Acta Neurochir(Wien), 2013, 155(3): 429-35.
|
[12] |
Valduvieco I, Verger E, Bruna J, et al. Impact of radiotherapy delay on survival in glioblastoma[J]. Clin Transl Oncol, 2013, 15 (4): 278-82.
|
[13] |
Chen YD, Feng J, Fang T, et al. Effect of intensity-modulated radiotherapy versus three-dimensional conformal radiotherapy on clinical outcomes in patients with glioblastoma multiforme[J]. Chin Med J(Engl), 2013, 126 (12): 2320-4.
|
[14] |
Roldán Urgoiti GB, Singh AD, Easaw JC. Extended adjuvant temozolomide for treatment of newly diagnosed glioblastoma multiforme[J]. J Neurooncol, 2012, 108(1): 173-7.
|
[15] |
Seiz M, Krafft U, Freyschlag CF, et al. Long-term adjuvant administration of temozolomide in patients with glioblastoma multiforme: experience of a single institution[J]. J Cancer Res Clin Oncol, 2010, 136(11): 1691-5.
|
[1] | LI Hongfei, TANG Weizhong, HUANG Qinglu, HUANG Kezeng, CAI Shangkun. Effect of Oxaliplatin on CD44V6, VEGF, survivin, Caspase-3 and Caspase-7 in Dimethylhydrazine-induced Colon Cancer Rats[J]. Cancer Research on Prevention and Treatment, 2015, 42(06): 560-563. DOI: 10.3971/j.issn.1000-8578.2015.06.006 |
[2] | Nie Yanli, Ruan Zhiping, Nan Kejun. Expressions of DR5,caspase-8,caspase-9 and caspase-3 in HepG2 Cell Line Treated with Gemcitabine[J]. Cancer Research on Prevention and Treatment, 2013, 40(02): 134-137. DOI: 10.3971/j.issn.1000-8578.2013.02.003 |
[3] | DING Hui, LI Xian-ming, GAO Yan, HU Li-xia, YANG Dong, ZHOU Ya-yan, XU Gang. Expression and Significance of HIF-2α and Caspase-3 in Nasopharyngeal Carcinoma[J]. Cancer Research on Prevention and Treatment, 2011, 38(01): 41-44. DOI: 10.3971/j.issn.1000-8578.2011.01.012 |
[4] | WANG Feng-qi, ZHAO Wei-ming, ZHANG Cheng, JIN Cheng-jun, ZHANG Zi-jian, ZHONG Zhao-hua, XIU You-cheng. Experimental of Combining Therapy with IL-12 Gene and THP in Bladder Cancer Nude Mice Model[J]. Cancer Research on Prevention and Treatment, 2010, 37(11): 1241-1244. DOI: 10.3971/j.issn.1000-8578.2010.11.008 |
[5] | WANG Ya-li, WANG Zhong-wei, WANG Xi-jing, JIN Ying-ying. Caspase-3 Gene of Mediating X radiation Induced Apoptosis in Nasopharyngeal Carcinoma[J]. Cancer Research on Prevention and Treatment, 2009, 36(07): 541-544. DOI: 10.3971/j.issn.1000-8578.2009.07.001 |
[6] | ZHANG Xiao-Juan, WANG Na, ZHOU Rong-Miao, DONG Xiu-Juan, LI Yan. Correlation of MMP-12 Polymorphism to Risk of Squamous Cell Carcinoma and Gastric Cardiac Adenocarcinoma[J]. Cancer Research on Prevention and Treatment, 2008, 35(10): 740-743. DOI: 10.3971/j.issn.1000-8578.2861 |
[7] | WANG Yan-yan, SONG Xing-fu, CUI Xiang-jun, HUANG Ji. Apoptosis Induced by Artesunate in Human Adenocarcinoma Cell Line A549 Cells Associated with Activation of caspase-9 and caspase-3[J]. Cancer Research on Prevention and Treatment, 2007, 34(09): 651-653. DOI: 10.3971/j.issn.1000-8578.2020 |
[8] | HUANG Wen-fang, YANG Yong-chang, LIU Hua, CHEN Jiang, ZHOU Ding-an. Changes of Caspase-3 and Caspase-9 Activity during the Simvastatin-induced Apoptosis in K562 Cells[J]. Cancer Research on Prevention and Treatment, 2007, 34(01): 39-41. DOI: 10.3971/j.issn.1000-8578.1221 |
[9] | YE Shu-nan, YANG Shu-hua, YANG Chao, XU Wei-hua. A Tumor-targeted Vector for Interleukin-12 Gene Therapy to Enhance the Anti-osteosarcoma Immunity in Nude Mouse[J]. Cancer Research on Prevention and Treatment, 2005, 32(05): 305-307. DOI: 10.3971/j.issn.1000-8578.2424 |
[10] | YE Shu-nan, YANG Shu-hua, WU Qiang, YANG Cao, LI Jing, XU Wei-hua. Polythylenimine AS A Nonviral Vector for Murine Interleukin-12 Gene Transfer to the Mouse Osteosarcoma Cells[J]. Cancer Research on Prevention and Treatment, 2005, 32(02): 96-98. DOI: 10.3971/j.issn.1000-8578.693 |